{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fidpodcast.simplecast.com%2Fepisodes%2Fcab-rpv-failure-Csuuu4mU","width":444,"version":"1.0","type":"rich","title":"Key Decisions in HIV Care: Assessing Candidacy for Long-Acting ART","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/86952976-b928-4317-884c-2c7ba3b2ae4d/9f777207-ea12-48b9-82e6-4bea17136389/key-decisions-mm-podcasticon-mm11.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/0e9aa063-7933-48ad-9364-61bba80489a3\" height=\"200\" width=\"100%\" title=\"Key Decisions in HIV Care: Assessing Candidacy for Long-Acting ART\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen as Milena Murray, PharmD, MSc, BCIDP, AAHIVP, shares the latest data about which patient factors may predict failure to LA CAB plus RPV and who is and who is not a good candidate for this new treatment option"}